Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer’s Disease
| Autor: | Ji Zeng, Xiaochuan Wang, Hui Wei, Hui-Liang Zhang, Dan Ke, Jia-Zhao Xie, Dong-Li Meng, Rong Liu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
business.industry Drug target Cancer Disease Protein phosphatase 2 medicine.disease environment and public health Biochemistry law.invention Serine 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Apoptosis law Cancer cell Genetics Cancer research Medicine Suppressor business 030217 neurology & neurosurgery |
| Zdroj: | Current Medical Science. 40:1-8 |
| ISSN: | 2523-899X 2096-5230 |
| DOI: | 10.1007/s11596-020-2140-1 |
| Popis: | SummaryProtein phosphatase 2A (PP2A) is a major serine/threonine phosphatase which participates in the regulation of multiple cellular processes. As a confirmed tumor suppressor, PP2A activity is downregulated in tumors and its re-activation can induce apoptosis of cancer cells. In the brains of Alzheimer’s disease (AD) patients, decreased PP2A activity also plays a key role in promoting tau hyperphosphorylation and Aβ generation. In this review, we discussed compounds aiming at modulating PP2A activity in the treatment of cancer or AD. The upstream factors that inactivate PP2A in diseases have not been fully elucidated and further studies are needed. It will help for the refinement and development of novel and clinically tractable PP2A-targeted compounds or therapies for the treatment of tumor and AD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink